Risedronate contains 35mg Risedronate Sodium.
Without a Prescription
Risedronate is prescribed for:
- For the treatment of bone thinning due to menopause in women;
- For the treatment of Paget's disease of the bone;
- Patients with bone related problems such as osteoporosis;
- To treat and prevent osteoporosis;
Risedronate is prescribed for treatment of Paget`s disease of bone in men and women. Treatment is prescribed in patients with Paget`s disease of bone (1) who have a level of serum alkaline phosphatase at least 2 times the upper limit of normal, or (2) who are symptomatic, or (3) who are at risk for future complications from their disease, to induce remission (normalization of serum alkaline phosphatase).
Risedronate is prescribed for the prevention and treatment of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage equivalent to 7.5 mg or greater of prednisone) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.
Osteoporosis in Men
Risedronate is prescribed for treatment to increase bone mass in men with osteoporosis.
Prevention of Osteoporosis
Risedronate may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of fracture. Factors such as family history of osteoporosis, previous fracture, smoking, BMD (at least 1 SD below the premenopausal mean), high bone turnover, thin body frame, Caucasian or Asian race, and early menopause are associated with an increased risk of developing osteoporosis and fractures. The presence of these risk factors may be important when considering the use of risedronate for prevention of osteoporosis.
Treatment of Osteoporosis
In postmenopausal women with osteoporosis, risedronate increases BMD and reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures. Osteoporosis may be confirmed by the presence or history of osteoporotic fracture, or by the finding of low bone mass.
Risedronate is prescribed for the treatment and prevention of osteoporosis in postmenopausal women.
Among the common side effects associated with the intake of Risedronate are:
- Joint Pains;
- Abdominal pains and discomforts;
Less common side effects of taking Risedronate are:
- Swelling of feet and lower legs;
- Ringing in the ears;
- General body malaise;
- Dry eyes;
- Chest pains;
- Blurry vision;
Risedronate may not work well with:
- Mineral supplements that contain calcium;
- Antacids that are calcium based or containing calcium;
The recommended treatment regimen is 30 mg orally once daily for 2 months. Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For retreatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than 1 course of retreatment.
Treatment and Prevention of Glucocorticoid -Induced Osteoporosis
The recommended regimen is - One 35 mg tablet orally, taken once a week.
Treatment to Increase Bone Mass in Men with Osteoporosis
The recommended regimen is - One 35 mg tablet orally, taken once a week
Treatment and Prevention of Postmenopausal Osteoporosis
The recommended regimen is - one 35 mg tablet orally, taken once a week.
Important Limitations of Use
The safety and effectiveness of Risedronate for the treatment of osteoporosis are based on clinical data of three years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.
- Known hypersensitivity to any component of this product;
- Inability to stand or sit upright for at least 30 minutes;
Risedronate is available in a blister pack of 4 tablets.